Details of the Drug Combination

General Information of Drug Combination (ID: DCFU2H6)

Drug Combination Name
Crizotinib Cyclophosphamide
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs Crizotinib   DM4F29C Cyclophosphamide   DM4O2Z7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: RXF 393
Zero Interaction Potency (ZIP) Score: 0.92
Bliss Independence Score: 4.44
Loewe Additivity Score: 1.07
LHighest Single Agent (HSA) Score: 1.07

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Crizotinib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [2]
Crizotinib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [8]
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Modulator [8]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Modulator [8]
HGF/Met signaling pathway (HGF/Met pathway) TTKA5LP NOUNIPROTAC Inhibitor [9]
------------------------------------------------------------------------------------
Crizotinib Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Crizotinib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Crizotinib Interacts with 45 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [13]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Activity [14]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Increases Response To Substance [6]
ALK tyrosine kinase receptor (ALK) OTV3P4V8 ALK_HUMAN Decreases Response To Substance [15]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Expression [5]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Decreases Expression [5]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Decreases Expression [5]
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Decreases Expression [5]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [16]
Acyl-CoA 6-desaturase (FADS2) OTUX531P FADS2_HUMAN Increases Expression [16]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [16]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [16]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [16]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [16]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Expression [16]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [16]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Phosphorylation [16]
Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C) OT6KFNMS CAC1C_HUMAN Decreases Activity [16]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Decreases Activity [16]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [6]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [6]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Decreases Secretion [17]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Decreases Secretion [17]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Activity [18]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [19]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [20]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Phosphorylation [19]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [21]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [22]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [22]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [23]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [24]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Decreases Phosphorylation [25]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [24]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [6]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [26]
Echinoderm microtubule-associated protein-like 4 (EML4) OTJC45TA EMAL4_HUMAN Increases Mutagenesis [22]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Activity [14]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Response To Substance [27]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Response To Substance [23]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [27]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Response To Substance [15]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Decreases Response To Substance [23]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Decreases Response To Substance [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 45 DOT(s)
Indication(s) of Cyclophosphamide
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [3]
Central nervous system neoplasm N.A. Approved [3]
Glioblastoma 2A00 Approved [3]
Immunodeficiency 4A00-4A85 Approved [3]
Inflammatory breast cancer 2C62 Approved [3]
Lupus nephritis 4A40.0Y Approved [3]
Lymphoma 2A80-2A86 Approved [3]
Multiple sclerosis 8A40 Approved [3]
Mycosis fungoides 2B01 Approved [3]
Plasma cell myeloma 2A83.1 Approved [3]
Solid tumour/cancer 2A00-2F9Z Approved [4]
Classic Hodgkin lymphoma N.A. Investigative [3]
Neuroblastoma 2D11.2 Investigative [3]
Retinoblastoma 2D02.2 Investigative [3]
Scleroderma 4A42 Investigative [3]
Cyclophosphamide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [34]
------------------------------------------------------------------------------------
Cyclophosphamide Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 4 (ABCC4) DTCSGPB MRP4_HUMAN Substrate [35]
------------------------------------------------------------------------------------
Cyclophosphamide Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [36]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Metabolism [37]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [38]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Metabolism [37]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [39]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [40]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [41]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Metabolism [42]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Cyclophosphamide Interacts with 225 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Increases Activity [43]
Cytochrome P450 2C18 (CYP2C18) OTY687L9 CP2CI_HUMAN Increases Activity [43]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [44]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Hydroxylation [45]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Increases ADR [28]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Increases Metabolism [46]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Decreases Activity [47]
Actin, cytoplasmic 1 (ACTB) OT1MCP2F ACTB_HUMAN Decreases Expression [48]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Expression [48]
Band 4.1-like protein 2 (EPB41L2) OT6UABPM E41L2_HUMAN Decreases Expression [49]
Receptor activity-modifying protein 1 (RAMP1) OT7UT2XB RAMP1_HUMAN Increases Expression [49]
Cystatin-F (CST7) OTQWZUVQ CYTF_HUMAN Decreases Expression [49]
Kelch repeat and BTB domain-containing protein 11 (KBTBD11) OTBOY3WH KBTBB_HUMAN Decreases Expression [49]
Aldehyde dehydrogenase 1A1 (ALDH1A1) OTCUWZKB AL1A1_HUMAN Increases Expression [49]
Carbonic anhydrase 2 (CA2) OTJRMUAG CAH2_HUMAN Decreases Expression [49]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Increases Expression [49]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Increases Expression [49]
Procathepsin L (CTSL) OTYTUW29 CATL1_HUMAN Increases Expression [49]
Galectin-1 (LGALS1) OT8LDFWR LEG1_HUMAN Increases Expression [49]
SPARC (SPARC) OTPN90H0 SPRC_HUMAN Increases Expression [49]
Pro-cathepsin H (CTSH) OTLFL0DG CATH_HUMAN Increases Expression [49]
Non-secretory ribonuclease (RNASE2) OT8Z4FNE RNAS2_HUMAN Decreases Expression [49]
Transcriptional regulator ERG (ERG) OTOTX9VU ERG_HUMAN Increases Expression [49]
Tissue factor (F3) OT3MSU3B TF_HUMAN Decreases Expression [49]
Cytochrome c oxidase subunit 7A2, mitochondrial (COX7A2) OTVT146E CX7A2_HUMAN Decreases Expression [49]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Decreases Expression [49]
Bactericidal permeability-increasing protein (BPI) OTNN9LJ5 BPI_HUMAN Decreases Expression [49]
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) OT0DH40W AL5AP_HUMAN Decreases Expression [49]
Interferon-induced GTP-binding protein Mx2 (MX2) OT05NF37 MX2_HUMAN Decreases Expression [49]
Amine oxidase A (MAOA) OT8NIWMQ AOFA_HUMAN Increases Expression [49]
Myeloblastin (PRTN3) OT72MHP7 PRTN3_HUMAN Decreases Expression [49]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Decreases Expression [49]
Caspase-1 (CASP1) OTZ3YQFU CASP1_HUMAN Decreases Expression [49]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Increases Expression [49]
Transmembrane 4 L6 family member 1 (TM4SF1) OTY0ECQN T4S1_HUMAN Increases Expression [49]
Intercellular adhesion molecule 3 (ICAM3) OTTZ5A5D ICAM3_HUMAN Decreases Expression [49]
P2Y purinoceptor 2 (P2RY2) OT47XN46 P2RY2_HUMAN Decreases Expression [49]
Glycine receptor subunit beta (GLRB) OTF37UG4 GLRB_HUMAN Increases Expression [49]
C-C chemokine receptor type 8 (CCR8) OTSCMH06 CCR8_HUMAN Decreases Expression [49]
Ras-related protein R-Ras2 (RRAS2) OT83NCEB RRAS2_HUMAN Increases Expression [49]
Bcl-2-interacting killer (BIK) OTTH1T3D BIK_HUMAN Decreases Expression [49]
Angiopoietin-1 (ANGPT1) OTVZ1NG3 ANGP1_HUMAN Increases Expression [49]
Fascin (FSCN1) OTTGIHTM FSCN1_HUMAN Increases Expression [49]
Pleckstrin homology-like domain family A member 2 (PHLDA2) OTMV9DPP PHLA2_HUMAN Increases Expression [49]
Testis-expressed protein 30 (TEX30) OT87WEPQ TEX30_HUMAN Decreases Expression [49]
Ras-related GTP-binding protein A (RRAGA) OTKISLG4 RRAGA_HUMAN Decreases Expression [49]
Cilium assembly protein DZIP1 (DZIP1) OTBVPO66 DZIP1_HUMAN Increases Expression [49]
RNA-binding protein with multiple splicing (RBPMS) OT1RDKR9 RBPMS_HUMAN Increases Expression [49]
Membrane-spanning 4-domains subfamily A member 3 (MS4A3) OT0CEJOO MS4A3_HUMAN Decreases Expression [49]
Rho GTPase-activating protein 7 (DLC1) OTP8LMCR RHG07_HUMAN Increases Expression [49]
MyoD family inhibitor domain-containing protein (MDFIC) OTSRYBWZ MDFIC_HUMAN Decreases Expression [49]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-12 (GNG12) OTOGF42G GBG12_HUMAN Increases Expression [49]
Cyclic AMP-dependent transcription factor ATF-5 (ATF5) OT03QCLM ATF5_HUMAN Decreases Expression [49]
PALM2-AKAP2 fusion protein (PALM2AKAP2) OTI618VF PLAK2_HUMAN Increases Expression [49]
Dihydropyrimidinase-related protein 4 (DPYSL4) OT3SBS2S DPYL4_HUMAN Increases Expression [29]
Integral membrane protein GPR137B (GPR137B) OT1CINQQ G137B_HUMAN Increases Expression [29]
Glutaminase kidney isoform, mitochondrial (GLS) OTGOZG2M GLSK_HUMAN Increases Expression [29]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Increases Expression [29]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Increases Expression [29]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [29]
Stomatin (STOM) OTC8R6EH STOM_HUMAN Increases Expression [29]
Cellular retinoic acid-binding protein 2 (CRABP2) OTY01V9G RABP2_HUMAN Increases Expression [29]
Tyrosine-protein kinase receptor UFO (AXL) OTKA2SUX UFO_HUMAN Increases Expression [29]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Increases Expression [29]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [29]
Tumor necrosis factor ligand superfamily member 9 (TNFSF9) OTV9L89D TNFL9_HUMAN Increases Expression [29]
Galectin-7 (LGALS7) OTMSVI7R LEG7_HUMAN Increases Expression [29]
Rho GDP-dissociation inhibitor 2 (ARHGDIB) OT9PD6CS GDIR2_HUMAN Increases Expression [29]
Epithelial membrane protein 1 (EMP1) OTSZHUHQ EMP1_HUMAN Increases Expression [29]
Epithelial membrane protein 3 (EMP3) OTODMJ1D EMP3_HUMAN Increases Expression [29]
Protein ripply3 (RIPPLY3) OT1HK35I DSCR6_HUMAN Increases Expression [29]
Pro-neuregulin-1, membrane-bound isoform (NRG1) OTZO6F1X NRG1_HUMAN Increases Expression [29]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Increases Expression [29]
Laminin subunit gamma-2 (LAMC2) OTJMTM72 LAMC2_HUMAN Increases Expression [29]
Filamin-C (FLNC) OT3F8J6Y FLNC_HUMAN Increases Expression [29]
Immediate early response gene 5 protein (IER5) OTJPTXMD IER5_HUMAN Increases Expression [29]
Keratin, type II cytoskeletal 80 (KRT80) OTAU54U3 K2C80_HUMAN Increases Expression [29]
Neuropilin and tolloid-like protein 2 (NETO2) OT0YAMC0 NETO2_HUMAN Increases Expression [29]
UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2 (B3GALNT2) OTOF6O2B B3GL2_HUMAN Increases Expression [29]
Phospholipase ABHD3 (ABHD3) OTH8P977 ABHD3_HUMAN Increases Expression [29]
Tumor necrosis factor receptor superfamily member 14 (TNFRSF14) OTB82PFO TNR14_HUMAN Increases Expression [29]
Major histocompatibility complex class I-related gene protein (MR1) OTZU3XX7 HMR1_HUMAN Increases Expression [29]
Tumor necrosis factor receptor superfamily member 27 (EDA2R) OTJLAIIH TNR27_HUMAN Increases Expression [29]
Stathmin-3 (STMN3) OT20F289 STMN3_HUMAN Increases Expression [29]
Solute carrier family 2, facilitated glucose transporter member 6 (SLC2A6) OTVUZCLG GTR6_HUMAN Increases Expression [29]
Endothelial protein C receptor (PROCR) OTRHED17 EPCR_HUMAN Increases Expression [29]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [30]
Interferon-related developmental regulator 1 (IFRD1) OT4SQMLQ IFRD1_HUMAN Decreases Expression [30]
Kinesin-like protein KIF21B (KIF21B) OTFXFIU3 KI21B_HUMAN Decreases Expression [30]
Large neutral amino acids transporter small subunit 3 (SLC43A1) OTQJQY3S LAT3_HUMAN Decreases Expression [30]
Cystatin-A (CSTA) OT1K68KE CYTA_HUMAN Decreases Expression [30]
Amino acid transporter heavy chain SLC3A2 (SLC3A2) OTBR33M9 4F2_HUMAN Decreases Expression [30]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [30]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [30]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Decreases Expression [30]
CCAAT/enhancer-binding protein beta (CEBPB) OTM9MQIA CEBPB_HUMAN Decreases Expression [30]
Protein EVI2A (EVI2A) OTR8RUXQ EVI2A_HUMAN Decreases Expression [30]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Decreases Expression [30]
DnaJ homolog subfamily B member 1 (DNAJB1) OTCOSEVH DNJB1_HUMAN Increases Expression [30]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Decreases Expression [30]
B-cell lymphoma 6 protein (BCL6) OTQAWWO1 BCL6_HUMAN Decreases Expression [30]
Radiation-inducible immediate-early gene IEX-1 (IER3) OTZJI5FZ IEX1_HUMAN Decreases Expression [30]
Cysteine--tRNA ligase, cytoplasmic (CARS1) OTOUZF6O SYCC_HUMAN Decreases Expression [30]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Decreases Expression [30]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [30]
DNA-binding protein inhibitor ID-2 (ID2) OT0U1D53 ID2_HUMAN Decreases Expression [30]
Early activation antigen CD69 (CD69) OTGJHSVP CD69_HUMAN Decreases Expression [30]
Transmembrane protein 267 (TMEM267) OTEAAVK7 TM267_HUMAN Decreases Expression [30]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [30]
Isopentenyl-diphosphate Delta-isomerase 1 (IDI1) OTGM06VJ IDI1_HUMAN Increases Expression [30]
N-arachidonyl glycine receptor (GPR18) OTL2VFIV GPR18_HUMAN Decreases Expression [30]
Nuclear receptor coactivator 7 (NCOA7) OT2CNBOG NCOA7_HUMAN Decreases Expression [30]
Alanine aminotransferase 2 (GPT2) OTS5VF7N ALAT2_HUMAN Decreases Expression [30]
Nanos homolog 1 (NANOS1) OT3UNZZY NANO1_HUMAN Increases Expression [30]
Heat shock protein 105 kDa (HSPH1) OTVRR73T HS105_HUMAN Increases Expression [30]
Insulin gene enhancer protein ISL-2 (ISL2) OT43PD2V ISL2_HUMAN Decreases Expression [30]
E3 ubiquitin-protein ligase pellino homolog 1 (PELI1) OTMLBCLC PELI1_HUMAN Decreases Expression [30]
Centriolar and ciliogenesis-associated protein HYLS1 (HYLS1) OT3SW5UC HYLS1_HUMAN Decreases Expression [30]
Tribbles homolog 3 (TRIB3) OTG5OS7X TRIB3_HUMAN Decreases Expression [30]
Glutathione-specific gamma-glutamylcyclotransferase 1 (CHAC1) OTJGE772 CHAC1_HUMAN Decreases Expression [30]
Transmembrane 6 superfamily member 1 (TM6SF1) OTQR4I2N TM6S1_HUMAN Decreases Expression [30]
Protein FAM107B (FAM107B) OT5RG4J0 F107B_HUMAN Decreases Expression [30]
Lysine-rich coiled-coil protein 1 (KRCC1) OTMMV6WZ KRCC1_HUMAN Decreases Expression [30]
DnaJ homolog subfamily B member 4 (DNAJB4) OTUD01BK DNJB4_HUMAN Increases Expression [30]
SLAM family member 5 (CD84) OTAY5B0F SLAF5_HUMAN Increases Expression [30]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [30]
Nuclear factor erythroid 2-related factor 3 (NFE2L3) OT1MGXT0 NF2L3_HUMAN Decreases Expression [30]
Dual specificity protein phosphatase 10 (DUSP10) OTNG467B DUS10_HUMAN Decreases Expression [30]
Apoptotic protease-activating factor 1 (APAF1) OTJWIVY0 APAF_HUMAN Decreases Expression [31]
Transmembrane protease serine 2 (TMPRSS2) OTN44YQ5 TMPS2_HUMAN Increases Expression [50]
Growth arrest-specific protein 2 (GAS2) OT50JKXQ GAS2_HUMAN Increases Expression [51]
Lysine-specific histone demethylase 1A (KDM1A) OT85JXS5 KDM1A_HUMAN Increases Expression [52]
Slit homolog 1 protein (SLIT1) OT35RBNT SLIT1_HUMAN Decreases Expression [32]
DnaJ homolog subfamily B member 6 (DNAJB6) OTMHIIAN DNJB6_HUMAN Increases Expression [51]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [53]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Increases Expression [54]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Increases Mutagenesis [55]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Mutagenesis [56]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Increases Expression [57]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [53]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Decreases Expression [58]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [59]
Heat shock 70 kDa protein 1A (HSPA1A) OTKGIE76 HS71A_HUMAN Increases Expression [60]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [61]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [62]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Phosphorylation [63]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Increases Expression [57]
Troponin I, cardiac muscle (TNNI3) OT65E12V TNNI3_HUMAN Increases Expression [57]
Tumor necrosis factor alpha-induced protein 3 (TNFAIP3) OTVLI4DD TNAP3_HUMAN Increases Expression [64]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [31]
Endothelin receptor type B (EDNRB) OTLLZV3P EDNRB_HUMAN Increases Expression [32]
Insulin-like growth factor-binding protein 5 (IGFBP5) OTRE5V0C IBP5_HUMAN Decreases Expression [32]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Decreases Methylation [52]
Proteasome subunit alpha type-5 (PSMA5) OT38E6Y1 PSA5_HUMAN Increases Expression [51]
HLA class I histocompatibility antigen, alpha chain F (HLA-F) OT76CM19 HLAF_HUMAN Increases Expression [32]
Phospholipid hydroperoxide glutathione peroxidase GPX4 (GPX4) OTRAFFX2 GPX4_HUMAN Increases Expression [51]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Expression [62]
Cytosolic purine 5'-nucleotidase (NT5C2) OTJMF66Z 5NTC_HUMAN Increases Expression [32]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Decreases Expression [64]
Potassium voltage-gated channel subfamily KQT member 4 (KCNQ4) OT29B58J KCNQ4_HUMAN Decreases Expression [32]
Heterogeneous nuclear ribonucleoprotein K (HNRNPK) OTNPRM8U HNRPK_HUMAN Increases Expression [51]
Protein BTG2 (BTG2) OTZF6K1H BTG2_HUMAN Increases Expression [31]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Decreases Expression [32]
Calicin (CCIN) OTRFZOT0 CALI_HUMAN Increases Expression [51]
Programmed cell death protein 4 (PDCD4) OTZ6NXUX PDCD4_HUMAN Decreases Expression [64]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [65]
Partitioning defective 3 homolog (PARD3) OTH5BPLO PARD3_HUMAN Decreases Expression [32]
GATOR1 complex protein NPRL2 (NPRL2) OTOB10MO NPRL2_HUMAN Decreases Expression [32]
F-box/WD repeat-containing protein 7 (FBXW7) OTJXE4OT FBXW7_HUMAN Increases Expression [31]
Rho guanine nucleotide exchange factor 26 (ARHGEF26) OTX0U8PX ARHGQ_HUMAN Increases Expression [32]
G-protein coupled receptor 20 (GPR20) OTPCR8F7 GPR20_HUMAN Increases Expression [32]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Decreases Expression [50]
Polyadenylate-binding protein-interacting protein 1 (PAIP1) OTL2F5T5 PAIP1_HUMAN Decreases Expression [32]
Large subunit GTPase 1 homolog (LSG1) OTDAXJ9L LSG1_HUMAN Decreases Expression [32]
Glyoxalase domain-containing protein 4 (GLOD4) OTBJKFXA GLOD4_HUMAN Decreases Expression [32]
DNA-directed DNA/RNA polymerase mu (POLM) OT0SRIP4 DPOLM_HUMAN Increases Expression [32]
Ubiquitin-like-conjugating enzyme ATG3 (ATG3) OT28VBVK ATG3_HUMAN Decreases Expression [32]
Regulator of telomere elongation helicase 1 (RTEL1) OTI3PJCT RTEL1_HUMAN Increases Expression [51]
FK506-binding protein-like (FKBPL) OTR9ND6K FKBPL_HUMAN Increases Expression [62]
Mitochondrial pyruvate carrier 2 (MPC2) OT0GHXGG MPC2_HUMAN Affects Response To Substance [33]
Krueppel-like factor 5 (KLF5) OT1ABI9N KLF5_HUMAN Affects Response To Substance [33]
Galactocerebrosidase (GALC) OT1F6BZK GALC_HUMAN Affects Response To Substance [33]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Affects Activity [66]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases ADR [28]
Krueppel-like factor 4 (KLF4) OT4O9RQW KLF4_HUMAN Decreases Response To Substance [67]
D-beta-hydroxybutyrate dehydrogenase, mitochondrial (BDH1) OT62RL5P BDH_HUMAN Affects Response To Substance [33]
Melanoma-associated antigen D1 (MAGED1) OT6EOLFC MAGD1_HUMAN Affects Response To Substance [33]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Affects Response To Substance [33]
Pro-adrenomedullin (ADM) OT7T0TA4 ADML_HUMAN Affects Response To Substance [33]
Peptidyl-prolyl cis-trans isomerase FKBP1B (FKBP1B) OT8CMPB2 FKB1B_HUMAN Affects Response To Substance [33]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Affects Response To Substance [33]
Epsilon-sarcoglycan (SGCE) OT9F17JB SGCE_HUMAN Affects Response To Substance [33]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Response To Substance [68]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Affects Response To Substance [69]
Sterol O-acyltransferase 1 (SOAT1) OTB4Y5RJ SOAT1_HUMAN Affects Response To Substance [33]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Affects Response To Substance [33]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [33]
Fibronectin type III domain-containing protein 3B (FNDC3B) OTBILGDR FND3B_HUMAN Affects Response To Substance [33]
Tropomyosin alpha-1 chain (TPM1) OTD73X6R TPM1_HUMAN Affects Response To Substance [33]
Very long chain fatty acid elongase 2 (ELOVL2) OTDAF6U3 ELOV2_HUMAN Affects Response To Substance [33]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases ADR [28]
Protein AF1q (MLLT11) OTG5RVHC AF1Q_HUMAN Decreases Response To Substance [70]
Troponin I, fast skeletal muscle (TNNI2) OTGGZFSC TNNI2_HUMAN Increases ADR [28]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [71]
Tomoregulin-1 (TMEFF1) OTH6M3CH TEFF1_HUMAN Affects Response To Substance [33]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [33]
Ribosomal protein S6 kinase alpha-2 (RPS6KA2) OTIOYUSU KS6A2_HUMAN Affects Response To Substance [33]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Response To Substance [72]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Affects Response To Substance [33]
Osteopontin (SPP1) OTJGC23Y OSTP_HUMAN Affects Response To Substance [33]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Affects Response To Substance [33]
Nidogen-1 (NID1) OTKLBLS6 NID1_HUMAN Affects Response To Substance [33]
Glutathione reductase, mitochondrial (GSR) OTM2TUYM GSHR_HUMAN Increases ADR [28]
Homeobox protein Hox-A1 (HOXA1) OTMSOJ7D HXA1_HUMAN Affects Response To Substance [33]
Trypsin-3 (PRSS3) OTN3S5YB TRY3_HUMAN Affects Response To Substance [33]
Melanoma-associated antigen D4 (MAGED4B) OTO37U7W MAGD4_HUMAN Affects Response To Substance [33]
Opsin-3 (OPN3) OTON6BFU OPN3_HUMAN Affects Response To Substance [33]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Affects Response To Substance [73]
Complement factor I (CFI) OTQYYX0P CFAI_HUMAN Affects Response To Substance [33]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Affects Response To Substance [33]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Affects Response To Substance [74]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Affects Response To Substance [33]
Glycogen debranching enzyme (AGL) OTWBM7WY GDE_HUMAN Affects Response To Substance [33]
Myosin-10 (MYH10) OTXN2WXS MYH10_HUMAN Affects Response To Substance [33]
Sal-like protein 1 (SALL1) OTYYZGLH SALL1_HUMAN Affects Response To Substance [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 225 DOT(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
3 Cyclophosphamide FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7154).
5 Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
6 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
7 Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012 Apr;24(4):852-8. doi: 10.1016/j.cellsig.2011.11.020. Epub 2011 Dec 8.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9 Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
10 Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
11 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
12 Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
13 Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013 Feb;41(2):343-52.
14 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
15 Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
16 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
17 Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
18 Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
19 ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
20 Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
21 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
22 Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.
23 Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2.
24 Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
25 Tyrosine phosphorylation of the scaffold protein IQGAP1 in the MET pathway alters function. J Biol Chem. 2020 Dec 25;295(52):18105-18121. doi: 10.1074/jbc.RA120.015891. Epub 2020 Oct 21.
26 Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. Toxicol Lett. 2020 Feb 1;319:102-110. doi: 10.1016/j.toxlet.2019.11.007. Epub 2019 Nov 7.
27 Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
28 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
29 Genomic profiling uncovers a molecular pattern for toxicological characterization of mutagens and promutagens in vitro. Toxicol Sci. 2011 Jul;122(1):185-97.
30 Transcriptome-based functional classifiers for direct immunotoxicity. Arch Toxicol. 2014 Mar;88(3):673-89.
31 Comparison of Drug Metabolism and Its Related Hepatotoxic Effects in HepaRG, Cryopreserved Human Hepatocytes, and HepG2 Cell Cultures. Biol Pharm Bull. 2018 May 1;41(5):722-732. doi: 10.1248/bpb.b17-00913. Epub 2018 Feb 14.
32 Effect of nephrotoxicants and hepatotoxicants on gene expression profile in human peripheral blood mononuclear cells. Biochem Biophys Res Commun. 2010 Oct 15;401(2):245-50. doi: 10.1016/j.bbrc.2010.09.039. Epub 2010 Sep 16.
33 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
34 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
35 Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4). AAPS J. 2010 Sep;12(3):300-8.
36 Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models. Exp Anim. 2018 Feb 9;67(1):71-82.
37 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
38 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
39 Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
40 CYP2C9 polymorphisms in human tumors. Anticancer Res. 2006 Jan-Feb;26(1A):299-305.
41 The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab Dispos. 2002 Jul;30(7):814-22.
42 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
43 Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics. 1997 Jun;7(3):211-21.
44 Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43.
45 Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cellsImpact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther. 2003 Aug;10(8):571-82.
46 Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro. 2001 Jun;15(3):245-56.
47 Qualitative defects of pseudocholinesterase activity. Anaesthesia. 1967 Jan;22(1):55-68.
48 Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002 Aug 9;449(3):197-205.
49 Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors. Leuk Res. 2007 Nov;31(11):1511-20.
50 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
51 Chronic cyclophosphamide exposure alters the profile of rat sperm nuclear matrix proteins. Biol Reprod. 2007 Aug;77(2):303-11. doi: 10.1095/biolreprod.107.060244. Epub 2007 May 2.
52 Cyclophosphamide perturbs cytosine methylation in Jurkat-T cells through LSD1-mediated stabilization of DNMT1 protein. Chem Res Toxicol. 2011 Nov 21;24(11):2040-3. doi: 10.1021/tx2003849. Epub 2011 Nov 1.
53 PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother Pharmacol. 2010 Sep;66(4):765-71. doi: 10.1007/s00280-009-1221-4. Epub 2009 Dec 30.
54 Suppression of spermatogenesis in patients with Beh?et's disease treated with cyclophosphamide and colchicine. Fertil Steril. 1981 Jul;36(1):76-80. doi: 10.1016/s0015-0282(16)45622-0.
55 Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
56 p53 mutations in cyclophosphamide-associated bladder cancer. Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):397-403.
57 Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. Int J Hematol. 2007 Jun;85(5):408-14. doi: 10.1532/IJH97.E0620.
58 Protein assay for heme oxygenase-1 (HO-1) induced by chemicals in HepG2 cells. J Toxicol Sci. 2009 Dec;34(6):709-14. doi: 10.2131/jts.34.709.
59 Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leukemia. 2008 Jan;22(1):179-85. doi: 10.1038/sj.leu.2404959. Epub 2007 Sep 27.
60 Induction of hsp 70 in HepG2 cells in response to hepatotoxicants. Toxicol Appl Pharmacol. 1996 Nov;141(1):117-23.
61 Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. Arch Toxicol. 2018 Jun;92(6):2043-2054. doi: 10.1007/s00204-018-2199-7. Epub 2018 Mar 29.
62 The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells. Breast Cancer Res Treat. 2003 Aug;80(3):239-44. doi: 10.1023/A:1024995202135.
63 Distinct Orchestration and Dynamic Processes on -H2AX and p-H3 for Two Major Types of Genotoxic Chemicals Revealed by Mass Spectrometry Analysis. Chem Res Toxicol. 2020 Aug 17;33(8):2108-2119. doi: 10.1021/acs.chemrestox.0c00104. Epub 2020 Jun 17.
64 Human embryonic stem cell derived hepatocyte-like cells as a tool for in vitro hazard assessment of chemical carcinogenicity. Toxicol Sci. 2011 Dec;124(2):278-90. doi: 10.1093/toxsci/kfr225. Epub 2011 Aug 27.
65 Validation of a genotoxicity test based on p53R2 gene expression in human lymphoblastoid cells. Mutat Res. 2011 Sep 18;724(1-2):76-85. doi: 10.1016/j.mrgentox.2011.06.003. Epub 2011 Jun 17.
66 Reduction of plasma fibrinolytic activity following high-dose cyclophosphamide is neutralized in vivo by GM-CSF administration. Haematologica. 1993 Mar-Apr;78(2):105-10.
67 Inhibition of glutathione synthesis reverses Krppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 2012 Feb;69(2):377-85. doi: 10.1007/s00280-011-1708-7. Epub 2011 Jul 22.
68 Important role of caspase-8 for chemosensitivity of ALL cells. Clin Cancer Res. 2011 Dec 15;17(24):7605-13. doi: 10.1158/1078-0432.CCR-11-0513. Epub 2011 Oct 18.
69 Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008 Nov;18(11):1009-15. doi: 10.1097/FPC.0b013e328313aaa4.
70 The evaluation of Cannabidiol's effect on the immunotherapy of Burkitt lymphoma. Biochem Biophys Res Commun. 2019 Nov 26;520(1):225-230. doi: 10.1016/j.bbrc.2019.10.001. Epub 2019 Oct 3.
71 [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
72 Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat. 2010 Nov;124(2):433-9. doi: 10.1007/s10549-010-0840-0. Epub 2010 Mar 23.
73 T-889C IL-1alpha promoter polymorphism influences the response to oral cyclophosphamide in scleroderma patients with alveolitis. Clin Rheumatol. 2007 Jan;26(1):88-91. doi: 10.1007/s10067-006-0308-0. Epub 2006 Apr 25.
74 Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol. 2005 Sep 1;23(25):6117-25. doi: 10.1200/JCO.2005.06.075. Epub 2005 Aug 8.